PARIS, Jan. 27, 2016 (GLOBE NEWSWIRE) — DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in vitro diagnostics for transplantation, infectious diseases and cancer, announces that its sales of in vitro diagnostic products increased by 4% and a consolidated income(1) as of December 31, 2015 at €29.5 million, compared to €30.6 million as of December 31, 2014, following the end of the collaboration with Allergan.

Total annual sales of in vitro diagnostic products reached €28.9 million, an increase of 4% compared to sales of €27.9 million recorded for the year 2014. This growth offsets to a large extent the end of the Allergan partnership and the corresponding revenues.

« Despite a French in vitro diagnostic market that was quite affected in 2015 with total yearly industry sales decreasing by 2,9% as of November 30, 2015, our sales of in vitro diagnostic products further increased by 4%. This performance validates our focus on specialty diagnostics, with an innovative product and service offering tailored to rapidly changing medical needs, » said Loïc Maurel, President of Diaxonhit Management Board. « In 2016, our group will be fully focused on specialty diagnostics, with innovative R&D, integrated manufacturing, a dynamic sales force, and the initial commercialization of two new proprietary products, AlloMap and BJI InoPlex, which benefit from new reimbursement systems for innovative tests that were recently introduced by the French Ministry of Health. »

Next financial release   : 2015 Full-year results, Thursday March 24, 2016 


Diaxonhit (Alternext, FR0004054427, ALEHT) is a French fully integrated leader in in vitro diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. It is the leader for commercialization in France of HLA tests. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network and a portfolio of proprietary products including Tetanus Quick Stick® and BJI Inoplex® in the field of infectious diseases. Each year, the Group invests in R&D more than 15% of its sales to develop new, innovative and proprietary diagnostic tests. Diaxonhit has 85 employees based in Paris and the Paris region. The Group is part of the Alternext BPI Innovation, PEA-PME 150 and Next Biotech indices.

For more information, please visit:

ISIN code : FR0004054427 – Reuters : ALEHT.PA – Bloomberg : ALEHT:FP

Media contacts

Hervé Duchesne de Lamotte, CFO, +33 1 53 94 77 55,

Julien Perez, Investor relations and financial communication, +33 1 44 71 98 52,
Annie-Florence Loyer, Media relations, +33 1 44 71 00 12,


This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated. In addition, DIAXONHIT, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

1 Income includes sales of in vitro diagnostic products and income related to R&D activities

Press Release